BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

766 related articles for article (PubMed ID: 26558340)

  • 1. Prevention of preterm birth with vaginal progesterone or 17-alpha-hydroxyprogesterone caproate: a critical examination of efficacy and safety.
    O'Brien JM; Lewis DF
    Am J Obstet Gynecol; 2016 Jan; 214(1):45-56. PubMed ID: 26558340
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluating Progestogens for Preventing Preterm birth International Collaborative (EPPPIC): meta-analysis of individual participant data from randomised controlled trials.
    EPPPIC Group
    Lancet; 2021 Mar; 397(10280):1183-1194. PubMed ID: 33773630
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Progestogens in singleton gestations with preterm prelabor rupture of membranes: a systematic review and metaanalysis of randomized controlled trials.
    Quist-Nelson J; Parker P; Mokhtari N; Di Sarno R; Saccone G; Berghella V
    Am J Obstet Gynecol; 2018 Oct; 219(4):346-355.e2. PubMed ID: 29614278
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vaginal progesterone compared with intramuscular 17-alpha-hydroxyprogesterone caproate for prevention of recurrent preterm birth in singleton gestations: a systematic review and meta-analysis.
    Boelig RC; Locci M; Saccone G; Gragnano E; Berghella V
    Am J Obstet Gynecol MFM; 2022 Sep; 4(5):100658. PubMed ID: 35562009
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Progestogens for Maintenance Tocolysis in Women With a Short Cervix: A Randomized Controlled Trial.
    Facchinetti F; Vergani P; Di Tommaso M; Marozio L; Acaia B; Vicini R; Pignatti L; Locatelli A; Spitaleri M; Benedetto C; Zaina B; DʼAmico R
    Obstet Gynecol; 2017 Jul; 130(1):64-70. PubMed ID: 28594783
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Progesterone and preterm birth prevention: translating clinical trials data into clinical practice.
    Society for Maternal-Fetal Medicine Publications Committee, with assistance of Vincenzo Berghella
    Am J Obstet Gynecol; 2012 May; 206(5):376-86. PubMed ID: 22542113
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vaginal progesterone vs intramuscular 17-hydroxyprogesterone caproate for prevention of recurrent preterm birth: a randomized controlled trial.
    Boelig RC; Schoen CN; Frey H; Gimovsky AC; Springel E; Backley S; Berghella V
    Am J Obstet Gynecol; 2022 May; 226(5):722.e1-722.e12. PubMed ID: 35189093
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 17 alpha-hydroxyprogesterone caproate does not prolong pregnancy or reduce the rate of preterm birth in women at high risk for preterm delivery and a short cervix: a randomized controlled trial.
    Winer N; Bretelle F; Senat MV; Bohec C; Deruelle P; Perrotin F; Connan L; Vayssière C; Langer B; Capelle M; Azimi S; Porcher R; Rozenberg P;
    Am J Obstet Gynecol; 2015 Apr; 212(4):485.e1-485.e10. PubMed ID: 25448515
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effectiveness of progestogens to improve perinatal outcome in twin pregnancies: an individual participant data meta-analysis.
    Schuit E; Stock S; Rode L; Rouse DJ; Lim AC; Norman JE; Nassar AH; Serra V; Combs CA; Vayssiere C; Aboulghar MM; Wood S; Çetingöz E; Briery CM; Fonseca EB; Worda K; Tabor A; Thom EA; Caritis SN; Awwad J; Usta IM; Perales A; Meseguer J; Maurel K; Garite T; Aboulghar MA; Amin YM; Ross S; Cam C; Karateke A; Morrison JC; Magann EF; Nicolaides KH; Zuithoff NP; Groenwold RH; Moons KG; Kwee A; Mol BW;
    BJOG; 2015 Jan; 122(1):27-37. PubMed ID: 25145491
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predictors of response to 17-alpha hydroxyprogesterone caproate for prevention of recurrent spontaneous preterm birth.
    Manuck TA; Esplin MS; Biggio J; Bukowski R; Parry S; Zhang H; Huang H; Varner MW; Andrews W; Saade G; Sadovsky Y; Reddy UM; Ilekis J;
    Am J Obstet Gynecol; 2016 Mar; 214(3):376.e1-8. PubMed ID: 26692181
    [TBL] [Abstract][Full Text] [Related]  

  • 11. What we have learned about the role of 17-alpha-hydroxyprogesterone caproate in the prevention of preterm birth.
    Caritis SN; Feghali MN; Grobman WA; Rouse DJ;
    Semin Perinatol; 2016 Aug; 40(5):273-80. PubMed ID: 27105940
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment options and recommendations to reduce preterm births in women with short cervix.
    Slager J; Lynne S
    J Midwifery Womens Health; 2012 Jul; 57 Suppl 1():S12-8. PubMed ID: 22776244
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A randomised trial to compare 200 mg micronised progesterone effervescent vaginal tablet daily with 250 mg intramuscular 17 alpha hydroxy progesterone caproate weekly for prevention of recurrent preterm birth.
    Shambhavi S; Bagga R; Bansal P; Kalra J; Kumar P
    J Obstet Gynaecol; 2018 Aug; 38(6):800-806. PubMed ID: 29557230
    [TBL] [Abstract][Full Text] [Related]  

  • 14. What agent should be used to prevent recurrent preterm birth: 17-P or natural progesterone?
    Hall NR
    Obstet Gynecol Clin North Am; 2011 Jun; 38(2):235-46, ix-x. PubMed ID: 21575799
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The rebirth of progesterone in the prevention of preterm labor.
    Schmouder VM; Prescott GM; Franco A; Fan-Havard P
    Ann Pharmacother; 2013 Apr; 47(4):527-36. PubMed ID: 23535817
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 17-alpha-hydroxyprogesterone caproate versus vaginal progesterone suppository for the prevention of preterm birth in women with a sonographically short cervix: A randomized controlled trial.
    Pirjani R; Heidari R; Rahimi-Foroushani A; Bayesh S; Esmailzadeh A
    J Obstet Gynaecol Res; 2017 Jan; 43(1):57-64. PubMed ID: 27775195
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In an in-vitro model using human fetal membranes, 17-α hydroxyprogesterone caproate is not an optimal progestogen for inhibition of fetal membrane weakening.
    Kumar D; Moore RM; Mercer BM; Mansour JM; Mesiano S; Schatz F; Lockwood CJ; Moore JJ
    Am J Obstet Gynecol; 2017 Dec; 217(6):695.e1-695.e14. PubMed ID: 29031893
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The safety of progesterone and 17-hydroxyprogesterone caproate administration for the prevention of preterm birth: an evidence-based assessment.
    O'Brien JM
    Am J Perinatol; 2012 Oct; 29(9):665-72. PubMed ID: 22773279
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A chronicle of the 17-alpha hydroxyprogesterone caproate story to prevent recurrent preterm birth.
    Nelson DB; McIntire DD; Leveno KJ
    Am J Obstet Gynecol; 2021 Feb; 224(2):175-186. PubMed ID: 33035472
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [The use of progestatives for the prevention of spontaneous preterm birth].
    Azria E
    J Gynecol Obstet Biol Reprod (Paris); 2016 Dec; 45(10):1280-1298. PubMed ID: 27776845
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 39.